US Sports Net Today!

Live Play-by-Play, Updates, Highlights and More! on US Sports Network!
[Chrome Users-You may have to click on the play button twice to listen]
US Sports Network Powered By Beast Sports Nutrition!

US Sports Radio
The Las Vegas Raiders Play Here
Fitness and Sports Performance Info You Can Use!
The Scoreboard Mall
The Rock Almighty Shaker Of Heaven And Earth!
The Coolest Links In The Universe!

Sunday, August 2, 2015

Brand-new therapy sends some cancers into total remission

A Promising New Cancer Therapy
That's Under Attack

In 2008-2009, four human studies appeared claiming fantastic results for a groundbreaking new cancer treatment. The studies were conducted Dr. Nabuto Yamamoto, who at the time was a Professor of Biochemistry at Temple University Medical School in Philadelphia. He was assisted by a team of other researchers.
If the results hold up, the new treatment – a natural enzyme found in a healthy human body — could be one of the most exciting new cancer developments ever seen.
In the first study, Dr. Yamamoto supplied the enzyme to doctors treating HIV patients — resulting in complete eradication of the infection. After seven years follow-up, their blood counts remained normal.
In another study, the Yamamoto team treated 16 nonanemic metastatic breast cancer patients with a single injection of 100 nanograms of GcMAF per week for 22 weeks. The treatment resulted in tumor eradication. Patients were well after four years follow-up.
In the third study, all 16 nonanemic metastatic prostate patients were tumor-free after 24 weeks and remained so at seven years follow-up.
In the fourth study, all eight nonanemic metastatic colorectal patients were cancer-free after 48 weeks and remained so at seven years follow-up as confirmed by CT scans.
In short – and astonishing as it sounds -- Professor Yamamoto achieved a 100% remission rate in metastatic cancer patients.
The discovery didn’t happen overnight. It was the product of years of research at a respected mainstream medical institution.

No comments:

Post a Comment